Old antibiotic, new hope? vancomycin trial for UC and PSC

NCT ID NCT07341282

Not yet recruiting Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether the antibiotic vancomycin can safely treat active ulcerative colitis in adults who also have primary sclerosing cholangitis, a liver condition. Fourteen participants will take vancomycin or a placebo for 4 weeks, with an optional 4-week extension. The main goal is to see if the study is feasible, while also checking for safety and early signs of benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vancomycin
What this could lead to: If it works, this could point toward a new treatment option for people with both ulcerative colitis and primary sclerosing cholangitis.
What could go wrong: This is a very small pilot study with only 14 participants, focused on feasibility. It is too early to know if vancomycin will actually improve symptoms or be safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS (PSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing primary sclerosing cholangitis ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SCLEROSING CHOLANGITIS (PSC) ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

McMaster Children's Hospital - Digestive Diseases Clinic

Hamilton, Ontario, L8N 3Z5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.